Methods
Sixty HIV negative volunteers randomised to 3 groups of 20, received DNA plasmid vaccine at 1 mg intradermally (i.d.) or 3.8 mg intramuscularly (i.m.) or placebo using the Biojector. DNA plasmids (KI/SMI and Vecura) containing HIV-1 gp160 subtypes A, B, C; rev B; p17/p24 gag A, B and Rtmut B were given (n = 59) at months 0, 1 and 3. A single boost of 10 8 pfu of recombinant MVA expressing HIV-1 env, gag, pol of CRF01_AE (NIAID and WRAIR) or placebo was administered i.m. (n = 50) at month 9. Interferon (IFN)-gamma ELISpot responses were measured after stimulation with peptide pools representing HIV-1 p17B, p24A, p55A, gp120A/B, gp120 B, gp41B, gp160E and PolA. Criteria for positive ELISpot responses were >55 spots/106 cells, >4 × background and >4 × baseline.
Results
Two weeks after the DNA injections, 13/19(68%) i.d. and 9/19(47%) i.m. vaccinees responded to Gag. Two weeks after the single MVA boost, all vaccine recipients responded: 35 (100%) to Gag and 31(89%) to Env peptide pools. The i.d. recipients reacted to more peptide pools than i.m. recipients; p = 0.007. While there was no significant difference between responders to the peptide pool spanning the Gag protein, there was a higher response to the Env gp160E peptide pool matching the boost, i.d. vs i.m. responders; median 415 (n = 17) vs median 187 (n = 12 ) p = 0.003.
Conclusion
Low dose, intradermal, multigene, multiclade HIV DNA elicited higher and broader immune responses compared to a higher dose given i.m. after a single boost with MVA containing heterologous HIV genes. All these Tanzanian vaccinees responded regardless of DNA priming route. In addition, env immune responses to the matched heterologous boost were higher in the i.d. DNA recipients. 
